Prosecution Insights
Prosecution Insights
7 pending office actions • 4 art units • 6 examiners • 0 of 7 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (14%) |
| Double-patenting + other | 3 (43%) |
| Multi-statute (no §101) | 3 (43%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOORE, SUSANNA | 2 | 68.0% | +31.6% |
| ARCORIA, PAUL JOSEPH | 1 | — | — |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.9% | +31.8% |
| HADDAD, MAHER M | 1 | 50.4% | +53.9% |
| TAYLOR, LIA ELAN | 1 | 64.4% | +29.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 6d |
| 18906683 | COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS, COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | ARCORIA, PAUL JOSEPH | — |
| 18292654 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | MOORE, SUSANNA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 6d |
| 18694190 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | RODRIGUEZ-GARCIA, VALERIE | — |
| 18292654 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | MOORE, SUSANNA | — |
| 18277931 | BISPECIFIC SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47 AND USE THEREOF | HADDAD, MAHER M | — |
| 18277914 | SINGLE DOMAIN ANTIBODY AGAINST CD47 AND USE THEREOF | TAYLOR, LIA ELAN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1641 | 2 |
| 1622 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18906683 | COMPOSITION FOR PREVENTING OR TREATING PULMONARY FIBROSIS, COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | ARCORIA, PAUL JOSEPH | — | §103§112 | Non-Final OA | — | Pending | Oct 04, 2024 |
| 18561881 | COMPOSITION FOR TREATMENT OF COVID-19 COMPRISING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | May 09, 2024 |
| 18694190 | COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS | RODRIGUEZ-GARCIA, VALERIE | 1621 | §102§103§112DP | Non-Final OA | — | Pending | Mar 21, 2024 |
| 18292654 | NOVEL COMPOUND THAT INHIBITS TNF-ALPHA GENERATION AND INFLAMMASOME ACTIVITY AND PREPARATION METHOD THEREFOR | MOORE, SUSANNA | 1624 | §102§112Other | Final Rejection | — | Pending | Jan 26, 2024 |
| 18277931 | BISPECIFIC SINGLE DOMAIN ANTIBODY TO PD-L1 AND CD47 AND USE THEREOF | HADDAD, MAHER M | 1641 | §102§112DP | Non-Final OA | — | Pending | Sep 22, 2023 |
| 18277914 | SINGLE DOMAIN ANTIBODY AGAINST CD47 AND USE THEREOF | TAYLOR, LIA ELAN | 1641 | §112DP | Final Rejection | — | Pending | Aug 18, 2023 |
| 18026888 | METHOD FOR MASS-PRODUCING SODIUM TAURODEOXYCHOLATE | MOORE, SUSANNA | 1624 | §103§112 | Final Rejection | 6d | Pending | Mar 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial